We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+17.44%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$633M
AUM Growth
+$139M
Cap. Flow
+$61.7M
Cap. Flow %
9.76%
Top 10 Hldgs %
97.05%
Holding
27
New
5
Increased
8
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$71.8M
2
KRRO icon
Korro Bio
KRRO
+$9.47M
3
GHRS icon
GH Research
GHRS
+$5.48M
4
DNLI icon
Denali Therapeutics
DNLI
+$2.82M
5
TRDA icon
Entrada Therapeutics
TRDA
+$1.83M

Top Sells

Rank Stock Value
1
STOK icon
Stoke Therapeutics
STOK
+$21M
2
IMTX icon
Immatics
IMTX
+$6.91M
3
XNCR icon
Xencor
XNCR
+$2.1M
4
ARWR icon
Arrowhead Research
ARWR
+$800K
5
MPLT
MapLight Therapeutics
MPLT
+$237K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
1
Stoke Therapeutics
STOK
$1.8B
$155M 24.51%
4,763,673
-641,001
-12% -$21M
GHRS icon
2
GH Research
GHRS
$1.93B
$151M 23.92%
10,763,288
+356,713
+3% +$5.48M
CGEM icon
3
Cullinan Oncology
CGEM
$1.01B
$127M 20.13%
8,963,500
– –
AGIO icon
4
Agios Pharmaceuticals
AGIO
$1.79B
$88.3M 13.96%
2,611,568
+2,531,944
+3,180% +$71.8M
DNLI icon
5
Denali Therapeutics
DNLI
$3.65B
$36.1M 5.71%
1,880,303
+141,553
+8% +$2.82M
CCCC icon
6
C4 Therapeutics
CCCC
$385M
$18.4M 2.91%
6,998,902
-99,231
-1% -$234K
KRRO icon
7
Korro Bio
KRRO
$150M
$17.4M 2.75%
1,538,296
+860,381
+127% +$9.47M
TCRX icon
8
TScan Therapeutics
TCRX
$48.6M
$8.1M 1.28%
8,019,148
– –
XNCR icon
9
Xencor
XNCR
$1.5B
$6.47M 1.02%
536,398
-169,160
-24% -$2.1M
DTIL icon
10
Precision BioSciences
DTIL
$180M
$5.42M 0.86%
985,113
-8,800
-0.9% -$40.6K
PASG icon
11
Passage Bio
PASG
$14.4M
$4.9M 0.77%
623,704
– –
NEUP
12
Neuphoria Therapeutics
NEUP
$21M
$3.56M 0.56%
875,328
+100
+0% +$423
TRDA icon
13
Entrada Therapeutics
TRDA
$264M
$2.67M 0.42%
211,689
+160,000
+310% +$1.83M
CGON icon
14
CG Oncology
CGON
$6.28B
$2.14M 0.34%
31,591
– –
IMTX icon
15
Immatics
IMTX
$1.18B
$2.14M 0.34%
216,973
-704,977
-76% -$6.91M
DSGN icon
16
Design Therapeutics
DSGN
$761M
$1.27M 0.2%
119,516
+50,000
+72% +$506K
YARW
17
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$973K 0.15%
+32,574
New +$950K
HOWL icon
18
Werewolf Therapeutics
HOWL
$17.2M
$548K 0.09%
657,786
+1,860
+0.3% +$1.27K
IBIO icon
19
iBio
IBIO
$69.5M
$129K 0.02%
+68,076
New +$158K
BOLT icon
20
Bolt Biotherapeutics
BOLT
$7.67M
$124K 0.02%
+30,800
New +$160K
PRQR icon
21
ProQR Therapeutics
PRQR
$243M
$111K 0.02%
68,486
– –
ABSI icon
22
Absci
ABSI
$1.32B
$63.7K 0.01%
+21,245
New +$61.5K
TRAW icon
23
Traws Pharma
TRAW
$6.85M
$27.6K ﹤0.01%
+15,078
New +$28.3K
APLT
24
DELISTED
Applied Therapeutics
APLT
– –
-410,500
Closed -$41K
ARWR icon
25
Arrowhead Research
ARWR
$11.9B
– –
-12,043
Closed -$800K
1
2

Similar funds

RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
SIC
SFE Investment Counsel Los Angeles, California $635M AUM 23.85% 1-Year Est. Return

Lynx1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Lynx1 Capital Management held 27 positions worth $633M, up 28% from $494M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Lynx1 Capital Management deployed $61.7M of net new capital in Q1 2026, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Yarrow Bioscience, Inc. Common Stock: 32,574 shares worth $973K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Stoke Therapeutics, an estimated $21M trimmed.

  • Lynx1 Capital Management's largest Q1 2026 buy was Yarrow Bioscience, Inc. Common Stock: 32,574 shares worth $973K.
  • Lynx1 Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $71.8M increase.
  • Lynx1 Capital Management's biggest Q1 2026 reduction was Stoke Therapeutics, cutting an estimated $21M.
  • Lynx1 Capital Management fully exited Arrowhead Research in Q1 2026, selling an estimated $800K.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $633M portfolio in Q1 2026.
  • Lynx1 Capital Management opened 5 new positions and closed 4 in Q1 2026.
  • Lynx1 Capital Management's portfolio value rose 28% quarter-over-quarter to $633M.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.